Modern views on β-adrenoblocker therapy in elderly patients with chronic heart failure
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Chronic heart failure (CHF) prevalence is maximal in the elderly. There are some important practical aspects of β-adrenoblocker therapy in this patient group. SENIORS study results provide new data on selective β-adrenoblocker / NO-dependent vasodilator nebivolol therapy perspectives in CHF patients aged over 70 years. Nebivolol safety and effectiveness in this population is discussed.
References
1. Yu.N. Belenkov, V.Yu. Mareev, F.T. Ageev Khronicheskaya serdechnaya nedostatochnost'. Izbrannye lektsii po kardiologii. Moskva «GEOTAR-Media» 2006.
2. Lopatin Yu.M. Evropeiskie rekomendatsii po diagnostike i lecheniyu khronicheskoi serdechnoi nedostatochnosti 2005g: novye pozitsii β-adrenoblokatorov. Con med 2005; 7(11): 926-31.
3. Fomin I.V., Belenkov Yu.N., Mareev V.Yu. i dr. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii - dannye EPOKhA-KhSN. Serd nedostat 2006; 7(3): 112-5.
4. Parameshwar J, Pool-Wilson PA, Sutton GC. Heart failure in a district general hospital. J Roy Coll Phys Lond 1992; 26: 139-42.
5. Lopatin Yu.M. Simpato-adrenalovaya sistema pri serdechnoi nedostatochnosti: rol' v patogeneze i vozmozhnosti korrektsii. Serd nedost 2003; 4(2): 105-6.
6. Skvortsov A.A., Mareev V.Yu. Beta-blokatory pri khronicheskoi serdechnoi nedostatochnosti: kakoi tip beta-adrenergicheskoi blokady predpochest'? Con med 2001; 3(2): 79- 82.
7. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341-62.
8. CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357(9266): 1385-90.
9. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9-13.
10. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001-7.
11. Packer M, Coats AJS, Fowler MB, for the Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS) Effect of Carvedilol on Survival in Severe Chronic Heart Failure. NEJM 2001; 344 (22): 1651-8.
12. Preobrazhenskii D.V., Pavlova A.V., Tarykina E.V. i dr. Ingibitory neirogumoral'nykh sistem v kompleksnoi terapii khronicheskoi serdechnoi nedostatochnosti. Cons med 2005; 7(11): 929-35.
13. Rylova A.K., Rozanov A.V. Terapiya β-blokatorami v spetsial'nykh gruppakh patsientov, stradayushchikh KhSN (obzor rezul'tatov analiza v podgruppakh issledovanii CIBIS II, COMET, COPERNICUS i MERIT HF). Serdtse 2003; 2(4): 193-6.
14. Patrianakos AP, Parthenakis FI, Mavrakis HE, et al. Effects of Nebivolol on left ventricular function and exercise capacity in patients with non-ischaemic dilated cardiomyopathy. A randomised placebo-controlled study. Hell J Cardiol 2005; 46(3): 199-207.
15. Komajda M, Follath F, Swedberg K, et al. The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology, The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Eur Heart J 2003; 24(5): 464-74.
16. Komajda M, Lapuerta, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005; 26(16): 1653-9.
17. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353(9146): 9-13.
18. Flather MD, Shibata MC, Coats AJS, et al. on behalf of the SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3): 215-25.
19. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001-7.
20. Packer M, Coats AJS, Fowler MB, for the Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS) Effect of Carvedilol on Survival in Severe Chronic Heart Failure. NEJM 2001; 344(22): 1651-8.
21. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥65 years of age. Am J Card 2001; 87(4): 413-9.
22. Coats AJS. Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure. A randomised, double-blind, placebo-controlled study. ESC Congress 2004, Munich. Ofitsial'nyi sait Evropeiskogo obshchestva kardiologov. www.escardio.org.
23. Altwegg LA, d’Uscio LV, Barandier C, et al. Nebivolol Induces NO-Mediated Relaxations of Rat Small Mesenteric But Not of Large Elastic Arteries. J Cardiovasc Pharmacol 2000; 36(3): 316- 20.
24. Andre DE, Arnet U, Yang Z, Luscher TF. Nebivolol Inhibits Human Aortic Smooth Muscle Cell Growth: Effects on Cell Cycle Regulatory Proteins. J Cardiovasc Pharmacol 2000; 35, (6): 845 - 8.
25. Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000; 36(5 Suppl 1): 401-3.
26. Brehm BR, Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49(2): 430-9.
27. Lenzen MJ, Scholte op Reimer WJM, Boersma E, et al. Differences between patients with a preserved and depressed left ventricular function: a report from EuroHeart Failure Survey; Eur Heart J 2004; 25(14): 1214-20.
28. Coats AJS. Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure. A randomised, double-blind, placebo-controlled study. ESC Congress 2004, Munich. Ofitsial'nyi sait Evropeiskogo obshchestva kardiologov. www.escardio.org
29. Georgescu A, Pluteanu F, Flonta M-L, et al. The cellular mech- anisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005; 508: 159-66.
30. Ghio S, Magrini G, Serio A, et al. on behalf of the SENIORS investigators Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006; 27(5): 562-8.
Review
For citations:
Privalova E.V. Modern views on β-adrenoblocker therapy in elderly patients with chronic heart failure. Cardiovascular Therapy and Prevention. 2007;6(3):94-99. (In Russ.)
Views:
439
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Email this article 
